Finance

Lists
RCEL:NASDAQ
AVITA Medical Inc
13,14 US$
+0,77%
(+0,10) 1D
13,14 US$
0,00% (0,00)
After hours
Closed: 19 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCEL...
Open
13,01 US$
High
13,44 US$
Low
12,70 US$
Mkt. cap
406,38 მლნ.
Avg. vol.
323,00 ათ.
Volume
19,00
52-wk high
13,73 US$
52-wk low
3,22 US$
EPS
-1,44 US$
Beta
1,99
Shares outstanding
30,93 მლნ.
No. of employees
226
Open
13,01 US$
High
13,44 US$
Low
12,70 US$
Mkt. cap
406,38 მლნ.
Avg. vol.
323,00 ათ.
Volume
19,00
52-wk high
13,73 US$
52-wk low
3,22 US$
EPS
-1,44 US$
Beta
1,99
Shares outstanding
30,93 მლნ.
No. of employees
226
News stories
From web sources and news partners
Profile
Avita Medical is a clinical and commercial company developing and marketing a range of regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts. Wikipedia
About AVITA Medical Inc
CEOჯეიმს კორბეტ
Employees226
Founded1999
HeadquartersValencia, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 3 analysts giving stock ratings to RCEL in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for RCEL in the last 3 months.
Highest
Current 13,14 US$
15,00 US$ (+14,16%)
Average
13,67 US$ (+4,03%)
Lowest
12,00 US$ (-8,68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ryan Zimmerman
BTIG
Buy
Maintained
15,00 US$
+14,2%
10/12/2026
Josh Jennings
TD Cowen
Buy
Maintained
14,00 US$
+6,5%
09/17/2026
Frank Takkinen
Lake Street
Buy
Reiterated
12,00 US$
-8,7%
08/28/2026
Chad Messer
Lake Street
Buy
Reiterated
6,00 US$
-54,3%
07/16/2026
Carl Byrnes
Northland Securities
Buy
Maintained
10,00 US$
-23,9%
03/26/2026
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
17,06 მლნ.
17,62 მლნ.
19,25 მლნ.
21,70 მლნ.
Cost of goods sold
3,19 მლნ.
3,30 მლნ.
3,52 მლნ.
3,94 მლნ.
Cost of revenue
3,19 მლნ.
3,30 მლნ.
3,52 მლნ.
3,94 მლნ.
Research and development expenses
3,75 მლნ.
5,69 მლნ.
5,63 მლნ.
5,08 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19,28 მლნ.
19,03 მლნ.
18,90 მლნ.
19,54 მლნ.
Operating expense
23,03 მლნ.
24,72 მლნ.
24,53 მლნ.
24,62 მლნ.
Total operating expenses
26,22 მლნ.
28,02 მლნ.
28,05 მლნ.
28,56 მლნ.
Operating income
-9,15 მლნ.
-10,41 მლნ.
-8,80 მლნ.
-6,86 მლნ.
Other non operating income
49,00 ათ.
737,00 ათ.
-95,00 ათ.
-12,00 ათ.
EBT including unusual items
-13,17 მლნ.
-11,64 მლნ.
-10,62 მლნ.
-7,63 მლნ.
EBT excluding unusual items
-12,27 მლნ.
-11,04 მლნ.
-10,32 მლნ.
-7,83 მლნ.
Income tax expense
15,00 ათ.
-17,00 ათ.
-11,00 ათ.
33,00 ათ.
Effective tax rate
-0,11%
0,15%
0,10%
-0,43%
Other operating expenses
-
-
-
-
Net income
-13,19 მლნ.
-11,62 მლნ.
-10,61 მლნ.
-7,66 მლნ.
Net profit margin
-77,29%
-65,97%
-55,12%
-35,31%
Earnings per share
-
-
-
-
Interest and investment income
300,00 ათ.
200,00 ათ.
-
500,00 ათ.
Interest expense
-3,47 მლნ.
-1,55 მლნ.
-1,42 მლნ.
-1,46 მლნ.
Net interest expenses
-3,17 მლნ.
-1,35 მლნ.
-1,42 მლნ.
-963,00 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-8,58 მლნ.
-9,76 მლნ.
-8,18 მლნ.
-6,25 მლნ.
Gain or loss from assets sale
252,00 ათ.
5,00 ათ.
55,00 ათ.
188,00 ათ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები